Table 1.
Characteristics of Study Participants by the Presence of Significant Coronary Stenosisa
| Total | Significant Coronary Stenosis |
|||
|---|---|---|---|---|
| Characteristic | (N = 674) | No (N = 610) | Yes (N = 64) | P value |
| Age (year) | 46 (41–51) | 46 (40–51) | 49 (46–54) | <.0001 |
| Male (%) | 63.4 | 62.0 | 76.6 | .02 |
| Family history of CAD (%) | 23.6 | 22.8 | 31.3 | .13 |
| Cocaine use (%) | 47.8 | 46.6 | 59.4 | .05 |
| Cocaine use >15 years | 38.1 | 36.9 | 50.0 | .04 |
| Cigarette smoking (%) | 83.4 | 82.6 | 90.6 | .10 |
| Alcohol use (%) | 86.4 | 86.2 | 87.5 | .78 |
| hsCRP ≥2 mg/dL (%) | 47.4 | 47.1 | 50.0 | .66 |
| hsCRP (mg/dL) | 1.8 (0.6–4.8) | 1.8 (0.6–4.8) | 2.1 (0.6–5.0) | .55 |
| Serum 25-hydroxy VD (ng/mL) | 17 (11–26) | 17.5 (11–26) | 14.5 (8–24) | .06 |
| VD deficiency (%) | 19.9 | 18.7 | 31.3 | .01 |
| Systolic BP (mm Hg) | 117 (107–128) | 116 (107–127) | 121 (111–129) | .08 |
| Diastolic BP (mm Hg) | 73 (67–82) | 73 (66–81) | 76 (69–85) | .08 |
| Glucose (mg/dL) | 85 (78–92) | 85 (78–92) | 86 (78–93) | .40 |
| BMI | 24.8 (22.0–29.1) | 24.8 (22.0–29.2) | 24.9 (21.7–27.7) | .26 |
| Baseline CD4 (cells/µL) | 329 (172–527) | 329 (172–527) | 319 (196–593) | .93 |
| Baseline viral load (copies/mL) | 11838 (643–64967) | 12000 (716–69131) | 8870 (494–32730) | .53 |
| Total cholesterol (mg/dL) | 163 (140–192) | 162 (139–191) | 170 (155–210) | .003 |
| LDL-C (mg/dL) | 86 (67–108) | 85 (66–106) | 98 (73–114) | .005 |
| HDL-C (mg/dL) | 51 (39–62) | 50(39–62) | 52 (36–63) | .69 |
| Triglycerides (mg/dL) | 105 (74–151) | 103 (72–148) | 132 (88–182) | .008 |
| Year of enrollment (%) | .0008 | |||
| 2003–2005 | 13.4 | 11.6 | 29.7 | |
| 2006–2007 | 16.5 | 16.6 | 15.6 | |
| 2008–2009 | 32.2 | 33.1 | 23.4 | |
| 2010–2011 | 38.0 | 38.7 | 31.3 | |
| Year of ART initiation (%) | .10 | |||
| Never initiated | 22.1 | 22.8 | 15.6 | |
| Before 1996 | 10.5 | 10.0 | 15.6 | |
| 1996–2003 | 30.9 | 30.5 | 34.3 | |
| 2004–2007 | 22.1 | 21.5 | 28.1 | |
| 2008–2010 | 14.4 | 15.2 | 6.3 | |
| NRTI use (month) | 17.9 (0.0–66.0) | 17.4 (0.0–65.0) | 25.0 (5.6–96.0) | .06 |
| NNRTI use (month) | 0 (0.0–12.0) | 0.0 (0.0–12.0) | 0.0 (0.0–16.5) | .79 |
| PI use (month) | 5.5 (0.0–48.0) | 5.0 (0.0–48.0) | 5.9 (0.0–48.5) | .70 |
| ART use (month) | 25.0 (0.9–82.0) | 24.0 (0.5–80.0) | 37.5 (11.0–98.0) | .07 |
| Framingham risk score | 4.0 (2.0–7.0) | 4.0 (2.0–7.0) | 7.0 (4.0–8.0) | <.0001 |
| Framingham score <10.0 (%) | 86.8 | 87.5 | 79.7 | .08 |
Abbreviations: ART, antiretroviral therapy; BMI, body mass index (kg/m2); BP, blood pressure; CAD, coronary artery disease; CD4, CD4 cell count; glucose, fasting glucose; hsCRP, high-sensitivity C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; VD, vitamin D; viral load, HIV RNA quantification.
a Median (interquartile range) for continuous variables, proportion (%) for categorical variables.